MX2007009914A - Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion. - Google Patents

Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion.

Info

Publication number
MX2007009914A
MX2007009914A MX2007009914A MX2007009914A MX2007009914A MX 2007009914 A MX2007009914 A MX 2007009914A MX 2007009914 A MX2007009914 A MX 2007009914A MX 2007009914 A MX2007009914 A MX 2007009914A MX 2007009914 A MX2007009914 A MX 2007009914A
Authority
MX
Mexico
Prior art keywords
radiation
mucosistis
chemotherapy
induced
estrogen receptor
Prior art date
Application number
MX2007009914A
Other languages
English (en)
Inventor
Heather A Harris
William Jacobson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36597596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007009914(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007009914A publication Critical patent/MX2007009914A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

La presente invencion provee un metodo para tratar o inhibir la mucositis o la cistitis por radiacion, utilizando un ligando selectivo para ER??; la presente invencion tambien provee composiciones, incluyendo composiciones farmaceuticas, que contienen el ligando selectivo para ER?? y un medicamento tradicional para la mucositis o cistitis por radiacion.
MX2007009914A 2005-02-16 2006-02-14 Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion. MX2007009914A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65337605P 2005-02-16 2005-02-16
PCT/US2006/005000 WO2006088784A1 (en) 2005-02-16 2006-02-14 Use of estrogen receptor-b selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis

Publications (1)

Publication Number Publication Date
MX2007009914A true MX2007009914A (es) 2007-09-25

Family

ID=36597596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007009914A MX2007009914A (es) 2005-02-16 2006-02-14 Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion.

Country Status (20)

Country Link
US (1) US20060211672A1 (es)
EP (1) EP1848427A1 (es)
JP (1) JP2008530210A (es)
KR (1) KR20070103456A (es)
CN (1) CN101119721A (es)
AR (1) AR053332A1 (es)
AU (1) AU2006214515A1 (es)
BR (1) BRPI0608154A2 (es)
CA (1) CA2596984A1 (es)
CR (1) CR9263A (es)
GT (1) GT200600064A (es)
IL (1) IL185009A0 (es)
MX (1) MX2007009914A (es)
NI (1) NI200700182A (es)
NO (1) NO20073901L (es)
PE (1) PE20061092A1 (es)
RU (1) RU2007128819A (es)
TW (1) TW200640451A (es)
WO (1) WO2006088784A1 (es)
ZA (1) ZA200706785B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641116A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of er.beta. selective ligands
JP5484914B2 (ja) 2007-01-22 2014-05-07 ジーティーエックス・インコーポレイテッド 核内受容体結合剤
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20150018398A1 (en) * 2013-07-15 2015-01-15 The Regents Of The University Of California Methods of using estrogen receptor-beta ligands as radiation mitigators
EP3906508B1 (en) * 2018-12-31 2024-03-13 Intel Corporation Securing systems employing artificial intelligence

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
CA2248013A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
NZ534348A (en) * 2000-01-28 2006-06-30 Endorech Inc Selective estrogen receptor modulators in combination with estrogens
US6685917B2 (en) * 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
WO2002064113A1 (en) * 2001-02-15 2002-08-22 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc

Also Published As

Publication number Publication date
CA2596984A1 (en) 2006-08-24
GT200600064A (es) 2006-11-09
NO20073901L (no) 2007-11-15
KR20070103456A (ko) 2007-10-23
TW200640451A (en) 2006-12-01
ZA200706785B (en) 2009-08-26
PE20061092A1 (es) 2006-12-05
EP1848427A1 (en) 2007-10-31
CR9263A (es) 2007-11-23
JP2008530210A (ja) 2008-08-07
RU2007128819A (ru) 2009-03-27
AU2006214515A1 (en) 2006-08-24
WO2006088784A1 (en) 2006-08-24
NI200700182A (es) 2008-05-13
IL185009A0 (en) 2008-08-07
US20060211672A1 (en) 2006-09-21
BRPI0608154A2 (pt) 2016-10-11
AR053332A1 (es) 2007-05-02
CN101119721A (zh) 2008-02-06

Similar Documents

Publication Publication Date Title
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
TW200716646A (en) (S)-N-methylnaltrexone
TW200642694A (en) Anti-M-CSF antibody compositions
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
RS20060320A (en) Substituted indazole-o-glucosides
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
MY142777A (en) Substituted indole-o-glucosides
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
UA87991C2 (en) Substituted indole-o-glucosides
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2008002492A (es) Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
TW200731991A (en) Lipophilic di(anticancer drug) compounds, compositions and related methods
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX2007009914A (es) Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion.
HK1115528A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
UA92180C2 (en) Benzimidazole thiophene compounds as plk inhibitors
DK1962822T3 (da) Terapi af maligne neoplasier